A Study to Investigate the Safety and Efficacy of NST-628 Oral Tablets in Subjects with Solid Tumors

Phase 1 trial, 230 patients

Trial opened April 2024 in Australia

Expanded to US Locations in September 2024

“Brief Summary

This is a two-part Phase 1, open label, multi-center, single arm, non-randomized, multiple dose, safety, pharmacokinetic (PK) and preliminary efficacy study of single agent NST-628 in adult patients with MAPK pathway mutated/dependent advanced solid tumors who have exhausted standard treatment options.”

NOTE: All interventional trials involve risk. 

So please consult with your oncology tem as well as ask questions of the trial researchers.

TRIAL NCT06326411

https://clinicaltrials.gov/study/NCT06326411?term=NST-628&rank=1

July 2024 Research paper

The Pan-RAF–MEK Nondegrading Molecular Glue NST-628 Is a Potent and Brain-Penetrant Inhibitor of the RAS–MAPK Pathway with Activity across Diverse RAS- and RAF-Driven Cancers

https://aacrjournals.org/cancerdiscovery/article/14/7/1190/746118/The-Pan-RAF-MEK-Nondegrading-Molecular-Glue-NST?fbclid=IwY2xjawFhngBleHRuA2FlbQIxMAABHdttC1b5cwhcYg7JuDX2zEAWUKMlWNzI8zvWbXU75MFqdJ7KsDgL2EQP_g_aem_CSoKefEvFRkeP6NbQIu8vA

March 2024

FDA Clears IND for NST-628 for Advanced Solid Tumors With RAS-MAPK Mutations

https://www.targetedonc.com/view/fda-clears-ind-for-nst-628-for-advanced-solid-tumors-with-ras-mapk-mutations?fbclid=IwY2xjawFhnelleHRuA2FlbQIxMAABHfkHeutb7U7MAh80tOFF2c9xk18X8Dh0ipYX-aCKHU3MDsML30ax1Ml4fg_aem_kotGeEV92v4GPQr0xJV3Dg